Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Conditions

Ovarian Neoplasms 8Breast Neoplasms 6Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 3Neoplasms 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Melanoma 2Lung Neoplasms 2Solid Tumors 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Nervous System Neoplasms 1Locally Advanced Rectal Cancer 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Central Nervous System Diseases 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Brain Metastases From Non-small Cell Lung Cancer 1Brain Diseases 1Advanced Solid Tumors 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × veliparib × Clear all
NCT01199224 2017-11-21

To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors

AbbVie

Phase 1 Completed
27 enrolled

Recurrence

NCT01193140 2012-11-21

To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

Abbott

Phase 2 Completed
24 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡